The Company was established in 2013 by Dr Michael Åkesson to pursue his invention improving the procedure of minimally invasive treatment in the condition of varicose vein. With the plan to capitalise on an eventual medical device, and after extensive research and development work the company filed for patent in 2015 which was granted and published in 2017.
Around the same time, the earning potential of the innovation – by then going under the name of Solutio - was noticed by two investors, LU Holding AB and Bononius AB, joining the company with the intention to commercialise the innovation. MedVASC AB is gaining momentum and has successfully applied for a 200,000-euro Medtech4Health grant from the Swedish innovation programme Vinnova.
The vision leading all company efforts now is to launch a market-winning product which will improve patients’ well-being, shorten the treatment procedure and provide security to doctors. MedVASC AB aims to make Solutio the standard for administering anaesthesia in varicose vein treatment. The company’s mission is to provide the most efficient and the safest treatment with minimum pain and maximum comfort to the patient.